How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.03. The company had revenue of $52.05 million for the quarter, compared to analyst estimates of $53.69 million. Global Blood Therapeutics had a negative net margin of 137.30% and a negative trailing twelve-month return on equity of 170.37%. The business's revenue for the quarter was up 41.1% on a year-over-year basis. During the same period last year, the company posted ($0.97) earnings per share.

What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?

20 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Glassdoor.com . Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Global Blood Therapeutics to a friend.

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU) , NVIDIA (NVDA) , Alibaba Group (BABA) , Exelixis (EXEL) , Pfizer (PFE) , AbbVie (ABBV) , Intel (INTC) , Advanced Micro Devices (AMD) , Gilead Sciences (GILD) and Block (SQ) .

When did Global Blood Therapeutics IPO?

Global Blood Therapeutics (GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

NASDAQ:GBT

Global Blood Therapeutics (GBT) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free GBT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $68.49
▼
$68.49
50-Day Range: $68.07
▼
$68.49
52-Week Range: $21.65
▼
$73.02

Volume: 74 shs
Average Volume: 2.07 million shs
Market Capitalization: $4.62 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Global Blood Therapeutics alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Global Blood Therapeutics Stock (NASDAQ:GBT)

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

GBT Stock News Headlines

March 25, 2024 | skift.com

Amex GBT to Acquire CWT for $570 Million

March 22, 2024 | msn.com

How Dr. Ted Love, a cardiologist turned biotech executive, sold his sickle cell company to Pfizer for $5.4B

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 5, 2024 | forbes.com

How Dr. Ted Love Sold Sickle Cell Company To Pfizer For $5.4 Billion

December 27, 2023 | msn.com

US biotech firm addresses critical gap in blood pressure management

December 20, 2023 | bbc.com

Should we pay people for donating blood?

November 13, 2023 | bizjournals.com

A serial biotech company founder has Parkinson's. His latest company is targeting a potentially game-changing therapy

November 8, 2023 | skift.com

Amex GBT Sees More Small Companies Needing Business Travel Help

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

November 8, 2023 | finance.yahoo.com

GBT Technologies Cancels and Voids Reverse Stock Split

October 6, 2023 | finance.yahoo.com

Global Peripheral Blood Mononuclear Cells Research Report 2023: R&D Revolution - PBMCs Paving the Way for Medical Breakthroughs

September 28, 2023 | benzinga.com

Diabetes Prevalence Continues To Rise – Better Therapeutics' Digital Treatment Could Help Change This Trajectory

July 28, 2023 | finance.yahoo.com

PFE Mar 2024 32.500 call

June 17, 2023 | benzinga.com

Gout Therapeutics Market Challenges, Drivers, Growth Opportunities, and Major Company Profiles 2023

June 14, 2023 | finance.yahoo.com

Global Patient Blood Management Market to Reach $23.6 Billion by 2030

June 12, 2023 | finance.yahoo.com

Global Lymphoma Therapeutics Market Report 2023: Sector is Expected to Reach $24.9 Billion by 2029 at a CAGR of 7.8%

June 11, 2023 | finance.yahoo.com

Global Health Study Validates Biospectal OptiBP Mobile Blood Pressure Measurement App Accuracy Across Diverse Settings

June 7, 2023 | bizjournals.com

Ted Love, now the chair of biotech's big trade group, talks drug access, leadership and 'crazy' co-pays

June 6, 2023 | finance.yahoo.com

GBT Received a Notice of Allowance for its Microchip Reliability Verification and Auto-Correction Patent Application

June 4, 2023 | es-us.finanzas.yahoo.com

The Global Non-insulin Diabetes Therapeutics Market

May 23, 2023 | msn.com

Pfizer Announces $5.4 Billion Deal to Acquire Global Blood Therapeutics

May 17, 2023 | marketwatch.com

(2023-2030) Anemia Drugs Market Size, Share and Trend Analysis Report, Worldwide Opportunities, Demand Forecast

May 11, 2023 | marketwatch.com

Artificial Blood Market, Global Outlook and Forecast 2023-2029

May 5, 2023 | marketwatch.com

2030 Blood Cancer Therapeutics Market Forecast: Positive Growth Trajectory Ahead

May 5, 2023 | finance.yahoo.com

Rare Disease Therapeutics Global Market Report 2023: Increasing Number of Patients with Rare Diseases Bolsters Growth

May 5, 2023 | finance.yahoo.com

Monoclonal Antibody Therapeutics Market to Surpass US$ 534.26 Billion by 2030, Says Coherent Market Insights (CMI)

May 5, 2023 | marketwatch.com

Metabolic Disorder Therapeutics Market 2023 Set to Growth Highest CAGR and Revenue by 2030

See More Headlines

Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GBT
CUSIP: N/A
CIK: 1629137
Web: www.gbt.com
Phone: (650) 741-7700
Fax: N/A
Employees: 457
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($5.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-303,090,000.00
Net Margins: -137.30%
Pretax Margin: -137.01%
Return on Equity: -170.37%
Return on Assets: -39.24%

Debt

Debt-to-Equity Ratio: 4.92
Current Ratio: 6.88
Quick Ratio: 6.17

Sales & Book Value

Annual Sales: $194.75 million
Price / Sales: 23.73
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.05 per share
Price / Book: 22.46

Miscellaneous

Outstanding Shares: 67,476,000
Free Float: 64,170,000
Market Cap: $4.62 billion
Optionable: Optionable
Beta: 0.45

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Ted W. Love M.D. (Age 63)
Pres, CEO & Director
Comp: $1.06M
Mr. Jeffrey S. Farrow (Age 60)
CFO & Principal Accounting Officer
Comp: $672.67k
Ms. Jung E. Choi (Age 52)
Chief Bus. & Strategy Officer
Comp: $645k
Mr. David L. Johnson (Age 53)
Chief Commercial Officer
Comp: $661.5k
Dr. Kim Smith-Whitley M.D. (Age 61)
Exec. VP and Head of R&D
Comp: $654k
Dr. David R. Phillips
Founder & Advisor
Dr. Matthew P. Jacobson Ph.D.
Founder & Advisor
Dr. Andrej Sali Ph.D.
Founder & Advisor
Ms. Nazila Habibizad (Age 59)
Exec. VP of Operations
Stephanie Yao
Sr. Director of Corp. Communications & Investor Relations

Key Competitors

View All Competitors

GBT Stock Analysis - Frequently Asked Questions

How were Global Blood Therapeutics' earnings last quarter?: Global Blood Therapeutics, Inc. (NASDAQ:GBT) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.03. The company had revenue of $52.05 million for the quarter, compared to analyst estimates of $53.69 million. Global Blood Therapeutics had a negative net margin of 137.30% and a negative trailing twelve-month return on equity of 170.37%. The business's revenue for the quarter was up 41.1% on a year-over-year basis. During the same period last year, the company posted ($0.97) earnings per share.
What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?: 20 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Global Blood Therapeutics to a friend.
What other stocks do shareholders of Global Blood Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ).
When did Global Blood Therapeutics IPO?: Global Blood Therapeutics (GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

This page (NASDAQ:GBT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Global Blood Therapeutics (GBT) Stock Price, News & Analysis

About Global Blood Therapeutics Stock (NASDAQ:GBT)

GBT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

GBT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info